AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 161 min read$AVR

Anteris Technologies (AVR) CFO discloses zero shares in first ownership filing

Anteris Technologies (AVR) CFO Moen Brent filed an initial Form 3, disclosing no equity holdings, transactions, or derivative positions. The filing serves as a baseline for future insider ownership disclosures.

Original reporting
stocktitan.net
Published Sep 16, 2026, 6:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 12:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$AVR
Neutral
high confidence
Mentioned
$AVR
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The filing provides a baseline for future insider activity monitoring but contains no material transaction.

02

Market read

Routine insider filing with no holdings; minimal impact on market perception.

03

What to watch

Potential upcoming equity grants or stock options not yet reflected in the filing.

Relevance 4/10Novelty 4/10Timing: filing disclosed today

Background

Form 3 is the initial beneficial ownership filing required when an officer becomes an insider.

Company-level read

Ticker impact

$AVRNeutralHigh confidence
Context

CFO Moen Brent filed an initial Form 3 showing zero stock and derivative holdings.

Expected impact

neutral

Evidence & confidence

The filing reports no holdings, so investors have no new insider buying or selling signal.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

Even a zero‑holding filing can signal future insider activity; watch for subsequent disclosures.

Key entities

  • company
    Anteris Technologies Global Corp.

    US‑listed biotech company (ticker AVR).

  • person
    Moen Brent

    Chief Financial Officer of Anteris.

Read at source← All news

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min